Robert A Goodnow

USPTO Granted Patents = 8 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 2.6

ph-index = 7

Forward Citations = 125(Granted Patents)

Company Filing History:

Chromalloy American Corporation

patents

3 out of 1,390

Iowa State University Research Foundation Inc

patents

4. 1 out of 1

Burns-biotec Laboratories, Inc.

patent

where one patent can have more than one assignee

Years Active: 1979-1985

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 4530832 - Method of vaccination for prevention of Bordetella bronchiseptica (1985-07-23),

2. D270283 - Nasal nozzle (1983-08-23),

3. 4381773 - Method and nozzle for nasal vaccination of immature mammals (1983-05-03),

4. 4300545 - Method and nozzle for nasal vaccination of immature mammals (1981-11-17),

5. 4203968 - Combination vaccine for swine dysentery and method of use (1980-05-20),

6. 4152415 - Method of increasing the effectiveness of oral vaccination for swine (1979-05-01),

7. 4152414 - Combination vaccine for swine dysentery and method of use (1979-05-01),

8. 4152413 - Oral vaccine for swine dysentery and method of use (1979-05-01),

Title: The Innovations of Robert A. Goodnow

Introduction: Robert A. Goodnow is an inventor based in Concord, MA (US). He is currently associated with Xrad Therapeutics, Inc. Although he has not yet been granted any patents, his work focuses on significant advancements in the field of oncology. Goodnow collaborates with notable colleagues, including Jianmin Fu and Yaode Wang, to develop innovative therapeutic solutions.

Latest Patent Applications: One of Goodnow's recent patent applications is titled "Dual ATM and DNA-PK Inhibitors for Use in Anti-Tumor Therapy." This application presents compounds of formula (I) and their pharmaceutically acceptable salts. The described compounds and their pharmaceutical compositions may be beneficial in treating oncologic diseases.

Conclusion: Robert A. Goodnow is making strides in the field of cancer therapy through his innovative research and collaborative efforts. His contributions, although not yet reflected in granted patents, hold promise for future advancements in oncology.

This text is generated by artificial intelligence and may not be accurate.